TrialCancer2017

Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Andrew J Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.